Silencing of Lactotransferrin expression by methylation in prostate cancer progression

被引:40
|
作者
Shaheduzzaman, Syed
Vishwanath, Anu
Furusato, Bungo
Cullen, Jennifer
Chen, Yongmei
Banez, Lionel
Nau, Martin
Ravindranath, Lakshmi
Kim, Kee-Hong
Mohammed, Ahmed
Chen, Yidong
Ehrich, Mathias
Srikantan, Vasantha
Sesterhenn, Isabell A.
McLeod, David G.
Vahey, Maryanne
Petrovics, Yorgy
Dobi, Albert
Srivastava, Shiv
机构
[1] Uniformed Serv Univ Hlth Sci, US Mil Canc Inst, Dept Surg, Ctr Prostate Dis Res, Rockville, MD 20852 USA
[2] Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA
[3] Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA
[4] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA
[5] WRAIR, Div Retrovirol, Rockville, MD USA
[6] SEQUENOM Inc, San Diego, CA USA
关键词
LTF; downregulation; methylation; PSA doubling time; chemoprevention;
D O I
10.4161/cbt.6.7.4327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer cells gain selection advantages by the coordinated silencing of protective and by the activation of cell proliferation/cell survival genes. Evaluations of epithelial cell transcriptome of benign and malignant prostate glands by laser capture microdissection (LCM) identified Lactotransferrin (LTF) as the most significantly downregulated gene in prostate cancer (CaP) cells (p < 10(-6)). Frequent downregulation, significant association of LTF with PSA recurrence-free survival in CaP patients and the established anti-tumorigenic effects of LTF in experimental cancer models have provided impetus to evaluate LTF expression features and mechanisms in CaP specimens. Methods: LTF mRNA expression analysis was performed in LCM derived benign and malignant prostate epithelial cells by using Affymetrix GeneChip and QRT-PCR. LTF protein expression was assessed in tissue specimens by immunohistochemistry and in serum samples from CaP patients compared to healthy male control by using ELISA. Mechanism of LTF downregulation was analyzed in 5-azadeoxycytidine treated LNCaP and LAPC4 cells using MALDI-TOF MS. Proliferation and cell cycle analysis of CaP cells by FACS flow cytrometry was assessed in LNCaP cell cultures. Results: Quantitative analysis of LTF mRNA expression in tumor cells revealed marked downregulation of LTF with significant associations to decreased PSA recurrence-free survival of CaP patients (n = 100, p <= 0.0322). Moreover, low levels of LTF protein expression was observed in tumor tissues as well as in sera from CaP patients (p <= 0.0001). LTF promoter downstream CpG island methylation was found in LNCaP and LAPCA cells. Furthermore, replenishing of LTF by supplementing growth media with LTF protein resulted in reduced cell growth. Cell cycle analysis revealed robust increases in apoptosis in response to LTF treatment. Conclusion: This study highlights the potential for LTF in chemoprevention and to become a biologically relevant prognostic marker of CaP, suggesting that silencing of the LTF gene may be causally linked to CaP progression.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [21] Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer
    Rybicki, Benjamin A.
    Rundle, Andrew
    Kryvenko, Oleksandr
    Chitale, Dhananjay
    Belinsky, Steven
    Tang, Deliang
    CANCER RESEARCH, 2016, 76
  • [22] Fibromodulin expression in human prostate cancer tissue: Implications for prostate cancer progression
    Padron, Estebana Ines Benedetti
    De Marzo, Angelo
    Del Valle, Javier Baena
    Geliebter, Jan
    Reyes, Niradiz
    CANCER RESEARCH, 2017, 77
  • [23] DNA methylation and silencing of gene expression
    Newell-Price, J
    Clark, AJL
    King, P
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (04): : 142 - 148
  • [24] Effects and mechanisms of frequent downregulation of lactotransferrin (LTF) in prostate cancer
    Shaheduzzaman, Syed
    Vishwanath, Anu
    Furusato, Bungo
    Cullen, Jennifer
    Chen, Yongmei
    Banez, Lionel L.
    Nau, Martin
    Ravindranath, Lakshmi
    Kim, Kee-Hong
    Mohamed, Ahmed
    Chen, Yidong
    Ehrich, Mathias
    Srikantan, Vasantha
    Sesterhenn, Isabell A.
    McLeod, David G.
    Vahey, Maryanne
    Petrovics, Gyorgy
    Dobi, Albert
    Srivastava, Shiv
    JOURNAL OF UROLOGY, 2007, 177 (04): : 224 - 225
  • [25] DNA Methylation of HOXD3 as a Marker of Prostate Cancer Progression
    Van der Kwast, T. H.
    Kron, K.
    Pethe, V.
    Briollais, L.
    Bapat, B.
    MODERN PATHOLOGY, 2010, 23 : 225A - 225A
  • [26] DNA methylation of HOXD3 as a marker of prostate cancer progression
    Kron, Ken J.
    Liu, Liyang
    Pethe, Vaijayanti V.
    Demetrashvili, Nino
    Nesbitt, Michael E.
    Trachtenberg, John
    Ozcelik, Hilmi
    Fleshner, Neil E.
    Briollais, Laurent
    van der Kwast, Theodorus H.
    Bapat, Bharati
    LABORATORY INVESTIGATION, 2010, 90 (07) : 1060 - 1067
  • [27] Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression
    Li, LC
    Chui, R
    Nakajima, K
    Oh, BR
    Au, HC
    Dahiya, R
    CANCER RESEARCH, 2000, 60 (03) : 702 - 706
  • [28] DNA Methylation of HOXD3 as a Marker of Prostate Cancer Progression
    Van der Kwast, T. H.
    Kron, K.
    Pethe, V.
    Briollais, L.
    Bapat, B.
    LABORATORY INVESTIGATION, 2010, 90 : 225A - 225A
  • [29] Somatic DNA methylation changes, epigenetic gene silencing, and prostate cancer prevention.
    Nelson, WG
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1962S - 1962S
  • [30] Methylation-mediated silencing of genes is not altered by selenium treatment of prostate cancer cells
    Ramachandran, Kavitha
    Navarro, Loida
    Gordian, Edna
    Das, Partha Manas
    Singal, Rakesh
    ANTICANCER RESEARCH, 2007, 27 (02) : 921 - 925